NASDAQ:ADTX

Aditxt Q4 2025 Earnings Results & Report

Aditxt logo
$0.0002 0.00 (0.00%)
As of 03:57 PM Eastern

Aditxt reported Q4 2025 earnings on March 31, 2026. The company reported EPS of $315,563.31.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
After Market Closes

Aditxt EPS Results

Actual EPS
$315,563.31
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Aditxt Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Aditxt's next earnings date is estimated for Wednesday, December 2, 2026, based on past reporting schedules.

Conference Call Resources

Aditxt Q4 2025 Earnings FAQ

Aditxt (NASDAQ:ADTX) reported earnings of $315,563.31 per share for Q4 2025. The report was announced on Tuesday, March 31, 2026.

Aditxt's next earnings date is estimated for Wednesday, December 2, 2026. MarketBeat tracks confirmed and estimated earnings dates for Aditxt on the company's earnings history page.

Aditxt Earnings Headlines

Aditxt Faces Nasdaq Delisting, Moves Fully to OTC
Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.tc pixel
Aditxt Stock Dividends | NASDAQ:ADTX | Benzinga
See More Aditxt Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aditxt? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aditxt and other key companies, straight to your email.

About Aditxt

Aditxt (NASDAQ:ADTX) is a biotechnology company focused on developing technologies for immune-system monitoring and modulation. Its AditxtScore platform is designed to measure and profile immune responses, with potential applications in tracking immune health and supporting personalized care.

The company has also pursued immune-reprogramming approaches intended to promote immune tolerance in areas such as autoimmune disease, allergies and transplant rejection. Through its operating businesses and strategic initiatives, Aditxt has expanded its activities into diagnostics and other health-related technologies.

View Aditxt Profile